Donepezil
| Evidence Level: L5 | Predicted Indications: 8 |
Table of Contents
- Donepezil
- Pharmacist Assessment Report
- Donepezil: Acetylcholinesterase inhibitor → psychogenic movement disorders
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Donepezil: Acetylcholinesterase inhibitor → psychogenic movement disorders
One-Sentence Summary
Donepezil is a cholinesterase inhibitor marketed in India as single-ingredient tablets and an orally disintegrating strip. The TxGNN model predicts it may be effective for psychogenic movement disorders, with a score of 0.9923. No clinical trials or publications were found for this disease, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | psychogenic movement disorders |
| TxGNN Prediction Score | 0.9923 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for donepezil is not available in the data compiled for this report. Donepezil is generally known as a cholinesterase inhibitor, which raises acetylcholine levels in the brain.
Psychogenic (functional) movement disorders are a different type of condition from the neurodegenerative disease for which donepezil is typically used. A cholinergic link to them is speculative and is not supported by any trial or publication retrieved for this report. The prediction should therefore be treated as a hypothesis only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Donepezil has 20 valid single-ingredient licences in the data compiled for this report, and none are cancelled. The records may be partial. None of the licence records carry approved-indication text.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 66691 | Donix 5mg Tablet | Strip of 10 tablets | Not recorded |
| 9809 | Alzidoc 5mg Tablet | Strip of 10 tablets | Not recorded |
| 63228 | Dorent 5mg Tablet | Strip of 10 tablets | Not recorded |
| 61548 | Donetaz ODS 5 Orally Disintegrating Strip | Strip of 1 disintegrating strip | Not recorded |
| 59883 | Donep-SR 23 Tablet | Strip of 10 tablets (SR) | Not recorded |
Safety Considerations
Package insert warnings and contraindications are not available in the data compiled for this report. Please refer to the package insert for safety information.
Drug Interactions: 257 interactions were recorded. Examples include:
- Major: Bupropion
- Moderate: Famotidine, Ranitidine, Cimetidine, Atropine, Hyoscyamine, Glycopyrronium, Dicyclomine, Dexamethasone, Metronidazole, Loperamide
- Minor: Acetylsalicylic acid, Aprepitant, Clarithromycin
Anticholinergic drugs (such as atropine, hyoscyamine and glycopyrronium) are listed among the moderate interactions.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a high model score (0.9923) but no clinical trials or publications for psychogenic movement disorders, so the evidence level is L5. Mechanistic support is speculative.
To proceed, the following is needed:
- Mechanism-of-action data for donepezil and a clearly argued link to psychogenic movement disorders
- Any preclinical or clinical studies directly addressing this condition
- Package insert warnings and contraindications for safety screening
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.